Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.…
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Aligos Therapeutics (NASDAQ: ALGS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 82 employees.
The shares were at 1.220 USD on 20 November 2026, down 82.7% over 52 weeks. Its 52-week range is 1.175 USD to 13.69 USD: the price is 91.1% below the high and 3.8% above the low.
Its market capitalisation is 7.62M USD.
Aligos Therapeutics reports return on equity of -45.2%, an operating margin of -215.5% and revenue up 287.2% year over year.
It holds more cash than debt, a net cash position of 19.19M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.